Alkermes’ Antipsychotic Clears US FDA Panel Amid Calls For Broader Professional Education Plan

 
• By Sue Sutter
FDA Advisory Committee Feature image
Alkermes proposes to market the drug to treat schizophrenia and bipolar disorder in adults. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers